Encapsulation of clozapine into polycaprolactone nanoparticles as a promising strategy of the novel nanoformulation of the active compound
Source abstract
Abstract
Clozapine (CLO), an atypical antipsychotic used in the clinic for treatment of schizophrenia, has a well-known efficacy, but its general use in clinical practice is limited because of the risk of serious side effects. Therefore, in the present work, we focused on the encapsulation of CLO into polymeric polycaprolactone nanoparticles (PCL NPs) and studies of interactions of this nanoformulation with model cells. Two types of clozapine PCL NPs (CLO-PCL NPs), pegylated and non-pegylated, were obtained by nanoemulsion templating method. The complex interactions of these NPs with three model cell lines (HEK 293, human embryonic kidney cell line; RAW 264.7, murine macrophage cell line; hCMEC/D3, model of blood-brain barrier, BBB) were studied. Cell viability, cellular uptake of NPs, NO release, expression of pro-inflammatory agents and transcytosis experiments were performed. Pegylated CLO-PCL NPs showed better results in the tests performed in the present study, in comparison to non-pegylated ones: they are not toxic to model cells; pegylated outer surface protected from their fast uptake by macrophages; they were not immunogenic; transcytosis experiments pointed to their ability to cross a model BBB. The results obtained in the present study indicate that pegylated CLO-PCL NPs are promising carrier for antipsychotic drugs directed to cross BBB. The experiments were conducted using only in vitro models but they provide valuable data in the field of nanotechnology which can be used in novel molecular pharmacology.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Nanoparticles: synthesis and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (70)
Show source-provided references
1. Abedini F, Ebrahimi M, Roozbehani AH, Domb A, Hosseinkhani H (2018) Overview on natural hydrophilic polysaccharide polymers in drug delivery. Polym Adv Technol 29:2564–2573. https://doi.org/10.1002/pat.437510.1002/pat.4375 ↗
2. Agrahari V, Agrahari V, Hung WT, Christenson LK, Mitra AK (2016) Composite nanoformulation therapeutics for long-term ocular delivery of macromolecules. Mol Pharm 6:2912–2922. https://doi.org/10.1021/acs.molpharmaceut.5b0082810.1021/acs.molpharmaceut.5b00828 ↗
3. Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505–515. https://doi.org/10.1021/mp800051m10.1021/mp800051m ↗
4. Ali FT, Abd El-Azeem EM, Hamed MA, Ali MAM, Abd Al-Kader NM, Hassan EA (2017) Redox dysregulation, immuno-inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: pathophysiological and phenotypic implications. Schizophr Res 188:98–109. https://doi.org/10.1016/j.schres.2017.01.01610.1016/j.schres.2017.01.016 ↗
5. Alibolandi M, Abnous K, Ramezani M, Hosseinkhani H, Hadizadeh F (2014) Synthesis of AS1411-aptamer-conjugated CdTe quantum dots with high fluorescence strength for probe labeling tumor cells. J Fluoresc 24:1519–1529. https://doi.org/10.1007/s10895-014-1437-510.1007/s10895-014-1437-5 ↗
6. Alibolandi M, Abnous K, Sadeghi F, Hosseinkhani H, Ramezani M, Hadizadeh F (2016) Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: in vitro and in vivo evaluation. Int J Pharm 16:162–178. https://doi.org/10.1016/j.ijpharm.2016.01.04010.1016/j.ijpharm.2016.01.040 ↗
7. Anton N, Saulnier C, Gaillard E, Porcher S, Vrignaud S, Benoit J (2009) Aqueous-core lipid nanocapsules for encapsulating fragile hydrophilic and/or lipophilic molecules. Langmuir 25:11413–11419. https://doi.org/10.1021/la901565q10.1021/la901565q ↗
8. Berardis D, Serroni N, Campanella D, Olivieri L, Ferri F, Carano A, Cavuto M, Martinotti G, Cicconetti A, Piersanti M, Saverio Moschetta F, Di Giannantonio M (2012) Update on the adverse effects of clozapine: focus on myocarditis. Curr Drug Saf 7:55–6210.2174/157488612800492681 ↗
9. Berardis D, Rapini G, Olivieri L, Nicola D, Tomasetti C, Valchera A, Fornaro M, Fabio F, Perna G, Nicola M, Serafini G, Carano A, Pompili M, Vellante F, Orsolini L, Martinotti G, Giannantonio M (2018) Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther Adv Drug Saf 9:237–256. https://doi.org/10.1177/204209861875626110.1177/2042098618756261 ↗
10. Chen ML, Wu S, Tsai TC, Wang LK, Tsai FM (2013) Regulation of macrophage immune responses by antipsychotic drugs. Immunopharmacol Immunotoxicol 35:573–580. https://doi.org/10.3109/08923973.2013.82874410.3109/08923973.2013.828744 ↗
11. da Costa Güllich AA, Coelho RP, Pilar BC, Ströher DJ, Galarça LA, Vieira SM, da Costa Escobar Piccoli J, Haas SE, Manfredini V (2015) Clozapine linked to nanocapsules minimizes tissue and oxidative damage to biomolecules lipids, proteins and DNA in brain of rats Wistar. Metab Brain Dis 30:695–702. https://doi.org/10.1007/s11011-014-9621-510.1007/s11011-014-9621-5 ↗
12. De Berardis D, Serroni N, Campanella D, Olivieri L, Marini S, Moschetta FS, Martinotti G, Di Giannantonio M (2013) Safety and efficacy of combined clozapineazathioprine treatment in a case of resistant schizophrenia associated with Behcet’s disease: a 2-year follow-up. Gen Hosp Psychiatry 35:213e9–213e11. https://doi.org/10.1016/j.genhosppsych.2012.06.00710.1016/j.genhosppsych.2012.06.007 ↗
13. Eigenmann DE, Xue G, Kim KS, Moses AV, Hamburger M, Oufir M (2013) Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studies. Fluids Barriers CNS 10:33-8118-10-33. https://doi.org/10.1186/2045-8118-10-3310.1186/2045-8118-10-33 ↗
14. Essali A, Al-Haj Haasan N, Li C, Rathbone J (2009) Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev (1):CD00005910.1002/14651858.CD000059.pub2 ↗
15. Farokhi M, Mottaghitalab F, Shokrgozar MA, Ou KL, Mao C, Hosseinkhani H (2016) Importance of dual delivery systems for bone tissue engineering. J Control Release 10:152–169. https://doi.org/10.1016/j.jconrel.2016.01.03310.1016/j.jconrel.2016.01.033 ↗
16. Fond G, Macgregor A, Miot S (2013) Nanopsychiatry—the potential role of nanotechnologies in the future of psychiatry: a systematic review. Eur Neuropsychopharmacol 23:1067–1071. https://doi.org/10.1016/j.euroneuro.2012.10.01610.1016/j.euroneuro.2012.10.016 ↗
17. Francesconi LP, Victorino AT, Salah IA, Cordova VH, Dias da Rosa E, Oliveira L, Jacobus RVM, Belmonte-de-Abreu PS, Ceresér KM (2018) Proinflammatory and anti-inflammatory biomarkers in schizophrenia and influence of simvastatin on the interleukin-6. Int Clin Psychopharmacol 19:84–88. https://doi.org/10.1097/YIC.000000000000024110.1097/YIC.0000000000000241 ↗
18. Ghadiri M, Vasheghani-Farahani E, Atyabi F, Kobarfard F, Mohamadyar-Toupkanlou F, Hosseinkhani H (2017) Transferrin-conjugated magnetic dextran-spermine nanoparticles for targeted drug transport across blood-brain barrier. J Biomed Mater Res A 105:2851–2864. https://doi.org/10.1002/jbm.a.3614510.1002/jbm.a.36145 ↗
19. Halperin A (1999) Polymer brushes that resist adsorption of model proteins: design parameters. Langmuir 15:2525–253310.1021/la981356f ↗
20. Hong S, Leroueil PR, Janus EK, Peters JL, Kober M, Islam MT, Orr BG, Baker JR, Banaszak MM (2006) Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability. Bioconjug Chem 17:728–734. https://doi.org/10.1021/bc060077y10.1021/bc060077y ↗
21. Howes OD, McCutcheon R, Agid O (2017) Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 174:216–229. https://doi.org/10.1176/appi.ajp.2016.1605050310.1176/appi.ajp.2016.16050503 ↗
22. Kadam RS, Bourne DW, Kompella UB (2012) Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance. Drug Metab Dispos 40:1380–1388. https://doi.org/10.1124/dmd.112.04492510.1124/dmd.112.044925 ↗
23. Khan W, Hosseinkhani H, Ickowicz D, Hong PD, Yu DS, Domb AJ (2012) Polysaccharide gene transfection agents. Acta Biomater 8:4224–4232. https://doi.org/10.1016/j.actbio.2012.09.02210.1016/j.actbio.2012.09.022 ↗
24. Khan IU, Serra CA, Anton N, Vandamme TF (2015) Production of nanoparticle drug delivery systems with microfluidics tools. Expert Opin Drug Deliv 12:547–56210.1517/17425247.2015.974547 ↗
25. Kim SS, Rait A, Kim E, DeMarco J, Pirollo KF, Chang EH (2015) Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. Cancer Lett 1:250–258. https://doi.org/10.1016/j.canlet.2015.08.02210.1016/j.canlet.2015.08.022 ↗
26. Kiran ASK, Kumar TSS, Sanghavi R, Doble M, Ramakrishna S (2018) Antibacterial and bioactive surface modifications of titanium implants by PCL/TiO2 nanocomposite coatings. Nanomaterials (Basel) 8. https://doi.org/10.3390/nano810086010.3390/nano8100860 ↗
27. Kirbay O, Geyik C, Guler E, Yesiltepe O, Gumus ZP, Demirkol O, Coskunol H, Timur S (2017) Testing of bioactive-nanovesicles on hepatotoxicity of atypical antipsychotics via digital holography. Colloids Surf B Biointerfaces 1:289–295. https://doi.org/10.1016/j.colsurfb.2017.01.00610.1016/j.colsurfb.2017.01.006 ↗
28. Kulkarni AS, Feng SS (2013) Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. Pharm Res 30:2512–2522. https://doi.org/10.1007/s11095-012-0958-310.1007/s11095-012-0958-3 ↗
29. Lee H, Larson RG (2008) Lipid bilayer curvature and pore formation induced by charged linear polymers and dendrimers: the effect of molecular shape. J Phys Chem B 112:12279–12285. https://doi.org/10.1021/jp805026m10.1021/jp805026m ↗
30. Leroueil PR, Berry SA, Duthie K, Han G, Rotello VM, McNerny DQ, Baker JR, Orr BG, Banaszak Holl MM (2008) Wide varieties of cationic nanoparticles induce defects in supported lipid bilayers. Nano Lett 8:420–424. https://doi.org/10.1021/nl072292910.1021/nl0722929 ↗
31. Li A, Yang F, Xin J, Bai X (2019) An efficient and long-acting local anesthetic: ropivacaine-loaded lipid-polymer hybrid nanoparticles for the control of pain. Int J Nanomedicine 31:913–920. https://doi.org/10.2147/IJN.S19016410.2147/IJN.S190164 ↗
32. Łukasiewicz S, Szczepanowicz K, Błasiak E, Dziedzicka-Wasylewska M (2015) Biocompatible polymeric nanoparticles as promising candidates for drug delivery. Langmuir. 31:6415–6425. https://doi.org/10.1021/acs.langmuir.5b0122610.1021/acs.langmuir.5b01226 ↗
33. Łukasiewicz S, Szczepanowicz K, Podgórna K, Błasiak E, Majeed N, Ogren SO, Nowak W, Warszyński P, Dziedzicka-Wasylewska M (2016) Encapsulation of clozapine in polymeric nanocapsules and its biological effects. Colloids Surf B Biointerfaces 140:342–352. https://doi.org/10.1016/j.colsurfb.2015.12.04410.1016/j.colsurfb.2015.12.044 ↗
34. Łukasiewicz S, Błasiak E, Szczepanowicz K, Guzik K, Bzowska M, Warszyński P, Dziedzicka-Wasylewska M (2017) The interaction of clozapine loaded nanocapsules with the hCMEC/D3 cells—in vitro model of blood brain barrier. Colloids Surf B Biointerfaces 1:200–210. https://doi.org/10.1016/j.colsurfb.2017.07.05310.1016/j.colsurfb.2017.07.053 ↗
35. Lupi M, Colombo C, Frapolli R, Ferrari R, Sitia L, Dragoni L, Bello E, Licandro AS, Falcetta F, Ubezio P, Bigini P, Salmona M, D'Incalci M, Morbidelli M, Moscatelli D (2014) A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma. Nanotechnology 25:335706. https://doi.org/10.1088/0957-4484/25/33/33570610.1088/0957-4484/25/33/335706 ↗
36. Maghraby GM, Williams AC, Barry BW (2006) Can drug-bearing liposomes penetrate intact skin? J Pharm Pharmacol 58:415–429. https://doi.org/10.1211/jpp.58.4.000110.1211/jpp.58.4.0001 ↗
37. Mainardes RM, Silva LP (2004) Drug delivery systems: past, present, and future. Curr Drug Targets 5:449–45510.2174/1389450043345407 ↗
38. Manjunath K, Venkateswarlu V (2005) Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 107:215–228. https://doi.org/10.1016/j.jconrel.2005.06.00610.1016/j.jconrel.2005.06.006 ↗
39. Mathaes R, Winter G, Besheer A, Engert J (2014) Influence of particle geometry and PEGylation on phagocytosis of particulate carriers. Int J Pharm 25:159–164. https://doi.org/10.1016/j.ijpharm.2014.02.03710.1016/j.ijpharm.2014.02.037 ↗
40. Meltzer HY, Huang M (2008) In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 172:177–197. https://doi.org/10.1016/S0079-6123(08)00909-610.1016/S0079-6123(08)00909-6 ↗
41. Milton Harris J, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214–221. https://doi.org/10.1038/nrd103310.1038/nrd1033 ↗
42. Moraes BS, Vieira SM, Salgueiro WG, Michels LR, Colomé LM, Avila DS, Haas SE (2016) Clozapine-loaded polysorbate-coated polymeric nanocapsules: physico-chemical characterization and toxicity evaluation in Caenorhabditis elegans model. J Nanosci Nanotechnol 16:1257–126410.1166/jnn.2016.11668 ↗
43. Mottaghitalab F, Farokhi M, Shokrgozar MA, Atyabi F, Hosseinkhani H (2015) Silk fibroin nanoparticle as a novel drug delivery system. J Control Release 28:161–176. https://doi.org/10.1016/j.jconrel.2015.03.02010.1016/j.jconrel.2015.03.020 ↗
44. Muthupandian S, Barik K, Mubarak D, Pugazhendhi A, Prakash P (2018) Synthesis of silver nanoparticles from Bacillus brevis (NCIM 2533) and their antibacterial activity against pathogenic bacteria. Microb Pathog 1:116–226. https://doi.org/10.1016/j.micpath.2018.01.03810.1016/j.micpath.2018.01.038 ↗
45. Nel A, Xia T, Mädler L, Li N (2006) Toxic potential mater. Nanolevel. 311:622–627
46. Omarch F, Kippie Y, Mentor S, Ebrahim N, Fisher D, Murilla G, Swai H, Dube A (2019) Comparative in vitro transportation of pentamidine across the blood-brain barrier using polycaprolactone nanoparticles and phosphatidylcholine liposomes. Artif Cells Nanomed Biotechnol 47:1428–1436. https://doi.org/10.1080/21691401.2019.159692310.1080/21691401.2019.1596923 ↗
47. Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F, Iasevoli F, Buonaguro EF, Fornaro M, Fiengo AL, Martinotti G, Mazza M, Perna G, Carano A, De Bartolomeis A, Di Giannantonio M, De Berardis D (2016) An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf 15:1329–1347. https://doi.org/10.1080/14740338.2016.120147510.1080/14740338.2016.1201475 ↗
48. Owens DE, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307:93–102. https://doi.org/10.1016/j.ijpharm.2005.10.01010.1016/j.ijpharm.2005.10.010 ↗
49. Panda A, Meena J, Katara R, Majumdar DK (2016) Formulation and characterization of clozapine and risperidone co-entrapped spray-dried PLGA nanoparticles. Pharm Dev Technol 21:43–53. https://doi.org/10.3109/10837450.2014.96532410.3109/10837450.2014.965324 ↗
50. Pang Z, Lu W, Gao H, Hu K, Chen J, Zhang C, Gao X, Jiang X, Zhu C (2008) Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release 4:120–127. https://doi.org/10.1016/j.jconrel.2008.03.00710.1016/j.jconrel.2008.03.007 ↗
51. Peng W, Jiang XY, Zhu Y, Omari-Siaw E, Deng WW, Yu JN, Xu XM, Zhang WM (2015) Oral delivery of capsaicin using MPEG-PCL nanoparticles. Acta Pharmacol Sin 26:139–148. https://doi.org/10.1038/aps.2014.11310.1038/aps.2014.113 ↗
52. Pollmächer T, Schuld A, Kraus T, Haack M, Hinze-Selch D (2001) On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors. Fortschr Neurol Psychiatr 69:65–74. https://doi.org/10.1055/s-2001-1653310.1055/s-2001-16533 ↗
53. Remington G, Lee J, Agid O, Takeuchi H, Foussias G, Hahn M, Fervaha G, Burton L, Powell H (2016) Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use. Exp Opin Drug Saf 15:1193–1203. https://doi.org/10.1080/14740338.2016.119146810.1080/14740338.2016.1191468 ↗
54. Saravanan M, Jacob V, Arockiaraj J, Prakas P (2014) Extracellular biosynthesis, characterization and antibacterial activity of silver nanoparticles synthesized by Bacillus subtilis (NCIM—2266). J Bionanosci 8:1–7. https://doi.org/10.1166/jbns.2014.120110.1166/jbns.2014.1201 ↗
55. Siskind D, McCartney L, Goldschlager R (2016) Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and metaanalysis. Br J Psychiatry 209:385–39210.1192/bjp.bp.115.177261 ↗
56. Stępnicki P, Kondej M, Kaczor AA (2018) Current concepts and treatments of schizophrenia. Molecules. 23. https://doi.org/10.3390/molecules2308208710.3390/molecules23082087 ↗
57. Szczęch M, Szczepanowicz K, Jantas D, Piotrowski M, Kida A, Lasoń W, Warszyński P (2017) Neuroprotective action of undecylenic acid (UDA) encapsulated into PCL nanocarriers. Colloids Surf Physicochem Eng Aspects 537:41–4710.1016/j.colsurfa.2017.07.009 ↗
58. Torchilin VP, Trubetskoy VS (1995) Which polymers can make nanoparticulate drug carriers long-circulating? Adv Drug Deliv Rev 16:141–15510.1016/0169-409X(95)00022-Y ↗
59. Verma A, Stellacci F (2010) Effect of surface properties on nanoparticle? Cell interactions. Small. 6:12–2110.1002/smll.200901158 ↗
60. Vermette P, Meagher L (2003) Interactions of phospholipid- and poly(ethylene glycol)-modified surfaces with biological systems: relation to physico-chemical properties and mechanisms. Colloids Surf B Biointerfaces 28:153–19810.1016/S0927-7765(02)00160-1 ↗
61. Vieira SM, Michels LR, Roversi K, Metz VG, Moraes BK, Piegas EM, Freddo RJ, Gundel A, Costa TD, Burger ME, Colomé LM, Haas SE (2016) A surface modification of clozapine-loaded nanocapsules improves their efficacy: a study of formulation development and biological assessment. Colloids Surf B Biointerfaces 1:748–756. https://doi.org/10.1016/j.colsurfb.2016.05.06510.1016/j.colsurfb.2016.05.065 ↗
62. Warnez S, Alessi-Severini S (2014) Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 14:102-244X-14-102. https://doi.org/10.1186/1471-244X-14-10210.1186/1471-244X-14-102 ↗
63. Weksler B, Romero IA, Couraud PO (2013) The hCMEC/D3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS 10:16-8118-10-16. https://doi.org/10.1186/2045-8118-10-1610.1186/2045-8118-10-16 ↗
64. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H (2012) Nanoparticles as drug delivery systems. Pharmacol Rep 64:1020–103710.1016/S1734-1140(12)70901-5 ↗
65. Xie X, Song J, Hu Y, Zhuang S, Wang Y, Zhao Y, Lu Q (2018) Tailor-made PL-UC-C3 nanoparticles for fluorescence/computed tomography imaging-guided cascade amplified photothermal therapy. Int J Nanomedicine 13:7633–7646. https://doi.org/10.2147/IJN.S18816910.2147/IJN.S188169 ↗
66. Xin X, Sha X, Jiang X, Zhang W, Chen L, Fang X (2012) Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials 33:8167–8176. https://doi.org/10.1016/j.biomaterials.2012.07.04610.1016/j.biomaterials.2012.07.046 ↗
67. Yeste J, Ill X, Alvarez M, Villa R (2018) Engineering and monitoring cellular barrier models. J Biol Eng 12:12–18. https://doi.org/10.1186/s13036-018-0108-510.1186/s13036-018-0108-5 ↗
68. Zhang Y, Kohler N, Zhang M (2002) Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 23:1553–156110.1016/S0142-9612(01)00267-8 ↗
69. Zhu B, Eurell T, Gunawan R, Leckband D (2001) Chain-length dependence of the protein and cell resistance of oligo(ethylene glycol)-terminated self-assembled monolayers on gold. J Biomed Mater Res 56:406–41610.1002/1097-4636(20010905)56:3<406::AID-JBM1110>3.0.CO;2-R ↗
70. Zhukova Y, Skorb EV (2017) Cell guidance on nanostructured metal based surfaces. Adv Healthc Mater 6. https://doi.org/10.1002/adhm.20160091410.1002/adhm.201600914 ↗